Amneal Pharmaceuticals (AMRX) Long-Term Debt Repayments: 2017-2025
Historic Long-Term Debt Repayments for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Sep 2025 value amounting to $2.6 billion.
- Amneal Pharmaceuticals' Long-Term Debt Repayments rose 4586.29% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 674.51%. This contributed to the annual value of -$188.9 million for FY2024, which is 54.38% up from last year.
- Latest data reveals that Amneal Pharmaceuticals reported Long-Term Debt Repayments of $2.6 billion as of Q3 2025, which was up 16,328.53% from $15.5 million recorded in Q2 2025.
- Amneal Pharmaceuticals' 5-year Long-Term Debt Repayments high stood at $2.6 billion for Q3 2025, and its period low was -$565.6 million during Q4 2023.
- Over the past 3 years, Amneal Pharmaceuticals' median Long-Term Debt Repayments value was $54.5 million (recorded in 2024), while the average stood at $200.2 million.
- Its Long-Term Debt Repayments has fluctuated over the past 5 years, first tumbled by 147.10% in 2023, then spiked by 4,586.29% in 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Long-Term Debt Repayments (Quarterly) stood at -$146.3 million in 2021, then crashed by 56.42% to -$228.9 million in 2022, then crashed by 147.10% to -$565.6 million in 2023, then surged by 43.02% to -$322.3 million in 2024, then spiked by 4,586.29% to $2.6 billion in 2025.
- Its Long-Term Debt Repayments was $2.6 billion in Q3 2025, compared to $15.5 million in Q2 2025 and $235.5 million in Q1 2025.